Valproic Acid Treatment of AIDS-Related Mania
J Clin Psychiatry 1997;58(9):406-407 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Mania has been widely reported in human immunodeficiency
virus (HIV)–infected patients and has been found to occur
at a higher incidence in patients with acquired immune
deficiency syndrome (AIDS) during the later stages of cognitive decline. When present, this condition poses significant challenges
to the care, safety, and medical management of the patient.
Standard treatments of mania, however, are often poorly
tolerated in this population. Lithium has been found to cause
significant neurologic toxicity at therapeutic levels, making it
a less attractive choice of treatment, and carbamazepine raises
considerable concern because of potential neutropenia.